Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072596 | 0.88 | MAPK14 (0.82) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5109793 | 0.86 | MAPK14 (0.66) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5116855 | 0.85 | MAPK14 (0.65) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5109261 | 0.85 | MAPK14 (0.62) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5123973 | 0.84 | MAPK14 (0.67) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5108797 | 0.83 | MAPK14 (0.64) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5110013 | 0.83 | MAPK14 (0.63) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5116730 | 0.82 | MAPK14 (0.62) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5116717 | 0.82 | MAPK14 (0.64) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 | |
| SCHEMBL5113172 | 0.82 | MAPK14 (0.61) | MAPK14MAP2K1HSPB1CYP2C9MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499600-B1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | claimed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1499600-B1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2006-04-27 | — | — | US | disclosed |
| EP-1499600-A1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093248-A1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 8/4885MAP2K1 67/4885HSPB1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.